Fertility preserving treatment for gynecologic malignancies: a review of recent literature
Authors:
- Juliet WolfordJWJuliet Wolford
- Krishnansu S. TewariKTKrishnansu S. Tewari
- 1 February 2020
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Obstetrics and Gynecology
- Vol. 32 (1) , 51-56
Abstract
Purpose of review: A significant number of women diagnosed with a gynecologic malignancy meet criteria for fertility-sparing treatment. Women are continuing to delay childbearing; the importance of fertility-sparing therapy is, therefore, increasing. It is imperative that physicians understand the options for, and limitations of, these treatments. Recent findings: Recent research has demonstrated improved outcomes for endometrial cancer by adding targeted hysteroscopic resection to progestin therapy. Cervical cancer research has focused on oncologic and pregnancy outcomes following management with radical trachelectomy, confirming its safety. Given the high rates of preterm birth following trachelectomy, studies have evaluated the adequacy of fertility counseling prior to treatment, and have looked for predictive factors for preterm birth. Additionally, research has shown a rise in the percentage of women receiving conservative treatment for both endometrial and cervical cancer. Summary: With an increasing number of women seeking conservative treatment, physicians must understand the safety and implications of such therapy. Retrospective studies have demonstrated the safety of fertility-sparing treatment for both endometrial and cervical cancer; prospective research is currently underway to provide better guidance for future directions of fertility-sparing treatment for gynecologic malignancies.Keywords
This publication has 28 references indexed in Scilit:
- National patterns of care and fertility outcomes for reproductive-aged women with endometrial cancer or atypical hyperplasiaAmerican Journal of Obstetrics and Gynecology, 2019
- Weight control is vital for patients with early-stage endometrial cancer or complex atypical hyperplasia who have received progestin therapy to spare fertility: a systematic review and meta-analysisCancer Management and Research, 2019
- Hysteroscopic Endometrial Focal Resection followed by Levonorgestrel Intrauterine Device Insertion as a Fertility-Sparing Treatment of Atypical Endometrial Hyperplasia and Early Endometrial Cancer: A Retrospective StudyJournal of Minimally Invasive Gynecology, 2019
- Treatment efficiency of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young women with endometrial atypical hyperplasia and endometrial cancerGynecologic Oncology, 2019
- A pilot study of gonadotropin-releasing hormone agonist combined with aromatase inhibitor as fertility-sparing treatment in obese patients with endometrial cancerJournal of Gynecologic Oncology, 2019
- Fertility preserving options for gynecologic malignancies: A review of current understanding and future directionsCritical Reviews in Oncology/Hematology, 2018
- Fertility-Preserving Treatment in Young Women With Grade 1 Presumed Stage IA Endometrial AdenocarcinomaInternational Journal of Gynecological Cancer, 2018
- Insulin resistance and overweight prolonged fertility-sparing treatment duration in endometrial atypical hyperplasia patientsJournal of Gynecologic Oncology, 2018
- Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine DeviceObstetrics & Gynecology, 2018
- Comparison of fertility-sparing treatments in patients with early endometrial cancer and atypical complex hyperplasiaMedicine, 2017